FirstLook Lung is a blood-based test that helps identify lung cancer risk before or alongside LDCT, for USPSTF-eligible adults. From DELFI Diagnostics. Backed by Menlo.
About the role
As DELFI's dedicated Market Access & Reimbursement leader, you will own and build the U.S. access strategy for DELFI's product lines end to end. You will translate DELFI's clinical and health-economic evidence into coding, coverage, and payment strategy that put our early cancer detection products into patient care.
What they're looking for
- Deep, current expertise in CMS/Medicare , including coverage and payment pathways, Medicare Administrative Contractors, LCD/NCD processes, MolDX, and diagnostic-specific pricing mechanisms such as ADLT, gapfill, and crosswalk
- Demonstrated track record securing coverage and payment with CMS and U.S. commercial payers, ideally including regional, integrated, and VA or federal payers
- Expertise in coding classification systems (CPT, HCPCS, ICD-10) and payer policies governing billing and compliance
- Proven ability to build strategy and execute hands-on as a sole functional owner, with the resourcefulness to operate without a team initially
- Excellent communication, presentation, and influencing skills, with a demonstrated ability to reconcile multiple stakeholder views and negotiate matters of significance with senior internal and external leaders
More about this role
About Us
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In...
Browse similar: Startup jobs · Remote jobs